Trial Profile
A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25mg and 50mg Compared to Glimepiride When Used in Combination with Metformin in Subjects with Type 2 Diabetes
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Fasiglifam (Primary) ; Glimepiride; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- 27 Dec 2013 Status changed from recruiting to discontinued, as reported by a Takeda media release.
- 28 Jun 2013 New trial record